Dr. Nancy Chan, MD

Dr. Chan practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Chan's NPI, 1275860892, was assigned on November 4, 2009. Dr. Chan graduated from State University of New York at Stony Brook, School of Medicine in 2008. Dr. Chan holds New York license 262360.

Dr. Chan's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Chan's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Chan is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Chan to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chan practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Chan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Chan is licensed in New York.

CMS data shows 220 Medicare services from Dr. Chan across 3 procedure codes in 2024, all of them office visits, for 123 Medicare patients. Medicare paid $25,352 for them. Every service was in an office.

CMS counts 123 Medicare patients who saw Dr. Chan in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have cancer, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chan's median patient age at 67, with 96% women.

In 2024, Dr. Chan wrote 84 Medicare Part D claims for 32 patients. 94% of them were for generic drugs. CMS names the drug for 53 of them, across 1 drug with 11 or more claims each, at $969 in total drug cost. In 2023, CMS named 121 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Chan for performance year 2024, reported as part of a group. Dr. Chan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chan as offering telehealth.

Dmand AI links 24 papers to Dr. Chan, published from 2016 to 2024. 2022 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Dr. Chan has published most often in Clin Cancer Res. Dr. Chan's most frequent co-authors are Jyoti Malhotra, MD, MPH, Joseph Aisner and Janice M. Mehnert.

Dmand AI links Dr. Chan to 11 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Chan that name 1 trial.

CMS Open Payments shows 23 general payments to Dr. Chan from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 91% of the total. Daiichi Sankyo Inc. paid the most, $7,087. It also lists 3 research payments totaling $15,795 from 2022 to 2024, naming 1 clinical trial.

Dr. Chan graduated from State University of New York at Stony Brook, School of Medicine in 2008.